| Market Cap | 11.86M | P/E | - | EPS this Y | 53.70% | Ern Qtrly Grth | - |
| Income | -7.37M | Forward P/E | -2.23 | EPS next Y | 47.50% | 50D Avg Chg | -1.00% |
| Sales | 667k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -32.00% |
| Dividend | N/A | Price/Book | 1.38 | EPS next 5Y | - | 52W High Chg | -71.00% |
| Recommedations | 2.00 | Quick Ratio | 2.38 | Shares Outstanding | 6.10M | 52W Low Chg | 91.00% |
| Insider Own | - | ROA | -57.46% | Shares Float | 1.67B | Beta | 0.65 |
| Inst Own | 9.80% | ROE | -157.62% | Shares Shorted/Prior | 202.21K/175.73K | Price | 2.90 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 22,788 | Target Price | 13.33 |
| Oper. Margin | -1,295.57% | Earnings Date | Nov 28 | Volume | 9,830 | Change | -4.29% |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.